Objective To explore the effect of individualized multiple-nutritional evaluation for patients with bone cancer. Methods Totals of 94 cases with bone cancer were divided into the control group and observation group(with 47 patients in each group) from January 2012 to December 2013. The control group received conventional nursing during chemotherapy, while the observation group was given individualized multiple-nutritional evaluation. The differences in serum albumin, level of dietary knowledge and the postoperative complications were compared at different periods of time. Results In the observation group, the serum albumin at admission and 1 week after admission were not significantly different (P >0. 05). After 4 weeks, the serum albumin of observation group was (33. 41 ± 1. 31) g/L, which was significantly different with the control group (t=5. 117,P<0. 05). In the observation group, the dietary knowledge at admission was not significantly different (P>0. 05). After 1 and 2 weeks, the dietary knowledge of observation group were (10.47 ±1. 33) and (9.56 ±1.28), which were significantly different with the control group (t =2. 935, 3. 297,respectively;P<0. 05). The complication of abdominal pain, diarrhea, abdominal distension and nausea and vomiting in the observation group were significantly lower than those of the control group (χ2 =6. 351, 4. 039,4. 663,4. 417,respectively;P<0. 05). Conclusions The individualized multiple-nutritional evaluation cannot only effectively improve the nutritional status of patients with bone cancer, but also reduce incidence of gastrointestinal complications.

BACKGROUND: Autophagy plays a crucial role in chemotherapy resistance of triple-negative breast cancer (TNBC). Hence, autophagy-related gene 5 (ATG5), an essential molecule involved in autophagy regulation, is presumably associated with recurrence of TNBC. This study was aimed to investigate the potential influence of single-nucleotide polymorphisms in ATG5 on the disease-free survival (DFS) of early-stage TNBC patients treated with anthracycline- and/or taxane-based chemotherapy. METHODS: We genotyped ATG5 SNP rs473543 in a cohort of 316 TNBC patients treated with anthracycline- and/or taxane-based chemotherapy using the sequenom's MassARRAY system. Kaplan-Meier survival analysis and Cox proportional hazard regression analysis were used to analyze the association between ATG5 rs473543 genotypes and the clinical outcome of TNBC patients. RESULTS: Three genotypes, AA, GA, and GG, were detected in the rs473543 of ATG5 gene. The distribution of ATG5 rs473543 genotypes was significantly different between patients with and without recurrence (P = 0.024). Kaplan-Meier survival analysis showed that patients carrying A allele of ATG5 rs473543 had an increased risk of recurrence and shorter DFS compared with those carrying the variant genotype GG in rs473543 (P = 0.034). In addition, after adjusting for clinical factors, multivariate Cox regression analyses revealed that the AA/GA genotype of rs473543 was an independent predictor for DFS (hazard risk [HR], 1.73; 95% confidence interval [CI], 1.04-2.87; P = 0.034). In addition, DFS was shorter in node-negative patients with the presence of A allele (AA/GA) than in those with the absence of A allele (P = 0.027). CONCLUSION ATG5 rs473543 genotypes may serve as a potential marker for predicting recurrence of early-stage TNBC patients who received anthracycline-and/or taxane-based regimens as adjuvant chemotherapy.
Adult ; Aged ; Anthracyclines ; administration & dosage ; adverse effects ; Autophagy-Related Protein 5 ; genetics ; Bridged-Ring Compounds ; administration & dosage ; adverse effects ; Chemotherapy, Adjuvant ; Disease-Free Survival ; Female ; Genetic Association Studies ; Genetic Predisposition to Disease ; Humans ; Kaplan-Meier Estimate ; Middle Aged ; Neoplasm Recurrence, Local ; drug therapy ; genetics ; pathology ; Polymorphism, Single Nucleotide ; genetics ; Taxoids ; administration & dosage ; adverse effects ; Triple Negative Breast Neoplasms ; drug therapy ; genetics ; pathology